Skylark Bio Expands Pipeline with First CNS Development Program, SKY-AS, Targeting UBE3A Restoration in Angelman Syndrome
Skylark Bio, a clinical-stage biotechnology company developing precision genetic medicines for monogenic disorders, is expanding its pipeline with SKY-AS, a differentiated gene therapy candidate designed to restore UBE3A expression in individuals with Angelman syndrome (AS). SKY-AS represents the company's first central nervous system (CNS) development program and expands Skylark's growing portfolio of precision, locally delivered genetic medicines.
Skylark Bio Doses First Patient in SONIX Phase 1/2 Trial of SKY-GJB2 for GJB2-Related Pediatric Deafness
Skylark Bio, a clinical-stage biotechnology company developing targeted genetic medicines for hearing loss and other monogenic disorders, today announced that the first patient has been dosed in the SONIX Phase 1/2 clinical trial evaluating SKY-GJB2, the Company’s investigational inner-ear-targeted gene therapy for GJB2-mediated hearing loss.
Skylark Bio to Present New Preclinical Data for its Pendrin Gene Therapy Program for Hearing Loss at ASGCT 2026
Skylark Bio, a biotechnology company developing targeted genetic medicines for hearing loss, today announced that it will present new preclinical data for SKY-PEN, its Pendrin gene therapy program in development for SLC26A4-related hearing loss, at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting.
